TREANDA® is a chemotherapy agent with alkylating properties, which means it can kill indolent B-cell NHL cells that have progressed. It has a unique design that combines two kinds of chemical structures. In a clinical study, TREANDA produced a robust response when used as a single agent to treat indolent B-cell NHL that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. In addition, TREANDA maintained duration of response, which is the amount of time the response to treatment lasts. In this study, overall response rates were 74% and the median duration of response was 9.2 months.*
TREANDA can be given in an outpatient setting. TREANDA is given through a needle that is put into your vein. This is called an intravenous infusion (IV). The infusion lasts for 60 minutes and is given on Days 1 and 2 of each 21-day treatment cycle. TREANDA may be given for up to 8 cycles.
If your healthcare professional feels that TREANDA is right for you, the information on this site will help you better understand this treatment option, and how it can power you on your road to remission.
* In a clinical study, TREANDA was examined alone (not combined with additional therapies). In total, 100 patients took TREANDA. The study included patients who were diagnosed with a form of indolent B-cell NHL and who had received prior treatment with rituximab or a rituximab-containing regimen and whose disease progressed during or within 6 months of treatment.
TREANDA for injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. TREANDA is also indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.
The following serious adverse reactions have been associated with TREANDA: myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation. Some of these reactions have been fatal, including myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN). Patients should be monitored closely for these reactions and treated promptly if any occur. Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment. Myelosuppression is frequently severe and should be expected when treating patients with TREANDA.
TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA.
The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.
Please see full Prescribing Information.